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Results At 8 weeks after treatment initiation, knee pain 
VAS scores were significantly lower in the Theracurmin 
group than in the placebo group, except in the patients with 
initial VAS scores of 0.15 or less. Theracurmin lowered 
the celecoxib dependence significantly more than placebo. 
No major side effects were observed with Theracurmin 
treatment.
Conclusion Theracurmin shows modest potential for the 
treatment of human knee osteoarthritis.
Introduction
Osteoarthritis, also referred to as degenerative joint disease, 
is a slow destructive process of the joints that affects mil-
lions of people worldwide. Although the exact biochemi-
cal cause of osteoarthritis remains unknown, the process 
usually begins when the joint structures are abnormal or 
the stress placed on joint surfaces is unusually high. Hip 
or knee osteoarthritis is a chronic condition that is usually 
treated with analgesics and nonsteroidal anti-inflammatory 
drugs (NSAIDs), but these drugs sometimes cause serious 
gastrointestinal and cardiovascular adverse events, espe-
cially with long-term use [1, 2]. Thus, there is a need for 
disease-modifying agents that not only decrease joint pain 
but also slow the progression of the condition.
Curcumin is a polyphenol extracted from turmeric, 
which has been safely used in foods such as curries for a 
long time [3]. Curcumin is a promising therapeutic food 
material because of its anti-inflammatory and antioxida-
tive functions, and has long been used as an anti-inflam-
matory treatment in traditional Chinese and Ayurvedic 
medicine [3]. Curcumin regulates various biochemical 
and molecular pathways by modulating several molecu-
lar targets, including transcription factors, cytokines, 
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enzymes, and genes regulating cell proliferation or 
apoptosis [4]. The anti-inflammatory effect of cur-
cumin seems to be comparable with those of steroidal 
drugs and NSAIDs such as indomethacin and phenylb-
utazone [5]. Some studies have shown that curcumin’s 
anti-inflammatory properties are related to the suppres-
sion of prostaglandin synthesis through its effect on 
cyclooxygenase (COX) [6], a key enzyme responsible 
for the conversion of arachidonic acid to prostaglandins. 
Curcumin has also been shown to inhibit proteasome 
activity and induce apoptosis in human colon cancer 
cells in vitro and in vivo [7]. It has also been suggested 
that an important mechanism of curcumin is inhibition 
of NF-kB activation [8], which is a key event in the 
chronic inflammatory process. Given these findings, 
curcumin is expected to be effective for a range of dis-
eases related to chronic inflammation, including cancer, 
cardiovascular disease, metabolic syndrome, Alzheimer 
disease, osteoarthritis, and other common diseases and 
aging conditions [3, 4, 9, 10]. Furthermore, it has been 
reported that curcumin can be a potent inhibitor of the 
production of inflammatory and catabolic mediators by 
chondrocytes [10]. Because osteoarthritis and related 
osteoarticular conditions of synovial joints are charac-
terized by inflammation, curcumin’s biological actions 
in joint tissues may facilitate the development of clini-
cally safe, orally administered therapeutic agents for 
treating joint diseases.
However, curcumin’s poor bioavailability has been an 
obstacle to realizing its beneficial health effects, because 
only a small amount of curcumin is absorbed with oral 
administration [11]. To overcome this bioavailability 
problem, we previously developed a surface-controlled 
water-dispersible curcumin and named it Theracurmin® 
(Theracurmin: Theravalues, Tokyo, Japan) [12]. The 
absorption efficacy of Theracurmin was investigated 
and compared with that of curcumin powder. In rats, the 
area under the blood concentration–time curve (AUC) 
after oral administration of Theracurmin was found to be 
more than 40-fold higher than that of curcumin powder. 
With healthy human volunteers, the AUC of Theracur-
min was 27-fold higher than that of curcumin powder. 
These findings demonstrated Theracurmin’s much higher 
bioavailability than those of currently available cur-
cumin preparations. Thus, Theracurmin is believed to be 
useful for providing the clinical benefits of curcumin in 
humans.
The purpose of this study was to determine the clini-
cal effects of orally administered Theracurmin in patients 
with knee osteoarthritis during 8 weeks of treatment. We 
hypothesized that Theracurmin ingestion for 8 weeks 
would improve the symptoms and functional abilities of 
patients with knee osteoarthritis.
Materials and methods
A randomized, double-blind, placebo-controlled, prospec-
tive clinical study was conducted to test our hypothesis in 
two treatment groups: Theracurmin and placebo. A total 
of 50 patients with knee osteoarthritis confirmed by radi-
ographic analysis were selected and enrolled in the study. 
Written informed consent was obtained from all subjects 
before participation. All procedures were reviewed and 
approved by the research ethics committee of our hospital, 
and this study was carried out in accordance with the World 
Medical Association’s Declaration of Helsinki.
The inclusion criteria were primary medial knee osteo-
arthritis patients over 40 years of age with Kellgren–Law-
rence grades of II or III upon radiographic classification. 
The exclusion criteria were previous knee surgeries, knee 
injection treatment during the study, knee steroid injections 
within 2 months before the study, or other steroid adminis-
tration within 4 weeks before the study. If patients needed 
NSAIDs during the study, oral celecoxib was prescribed, 2 
pills per day (100 mg per pill). The other combined therapy 
we allowed was pain relief patches.
Theracurmin or placebo was administered orally twice a 
day for 8 weeks. Subjects in the Theracurmin group took 6 
capsules of Theracurmin per day, which contained 180 mg 
of curcumin. Similarly, subjects in the placebo group took 
6 placebo capsules per day, which had a similar shape and 
color to those of the Theracurmin capsules; the capsules 
were primarily made of starch, dextrin, and maltose. The 
subjects were requested to report the number of capsules 
remaining and celecoxib pills prescribed at their week 2, 
4, 6, and 8 visits at our outpatient clinic for the compliance 
check.
Blood biochemistry analyses were performed before 
the study and after 8 weeks of each intervention. The 
patients’ knee symptoms were evaluated at 0, 2, 4, 6, 
and 8 weeks according to the following criteria: the 
Japanese Knee Osteoarthritis Measure (JKOM) [13], the 
knee pain visual analog scale (VAS) included in JKOM, 
and the knee scoring system of the Japanese Orthopedic 
Association (JOA) [14]. JKOM consists of 25 questions 
divided into 4 subcategories—pain and stiffness, condi-
tion in daily life, general activities, and health condi-
tions—for patient self-assessment, and is based on the 
World Health Organization’s International Classification 
of Functioning, Disability, and Health. It is validated in 
the same manner as the Western Ontario and McMaster 
Universities’ Arthritis Index (WOMAC). The JOA scale 
evaluates four items: ability to walk (30 points), ability to 
climb up and down stairs (25 points), range of motion (35 
points), and joint swelling (10 points). Each knee joint 
can achieve a maximum score of 100 points on the JOA 
scale. We used the improved JKOM, VAS, and JOA scores 
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(the differences between the scores at each time point and 
those before the study). We evaluated adverse events and 
the number of celecoxib pills that the subjects needed 
during the 8-week period.
The two-sample one-sided t test was used to perform the 
statistical analysis of the VAS, JKOM, and JOA scores. The 
chi-square test was used to analyze the need for celecoxib. The 
level of statistical significance was set to a P value of <0.05.
Results
Drop-outs from the study are shown in Fig. 1. Three sub-
jects (two and one in the Theracurmin and placebo groups, 
respectively) did not attend follow-up at weeks 1, 2, and 
6. The other three patients discontinued participation in 
the study because of minor side effects. One patient in 
the Theracurmin group had a feeling of tachycardia and 
hypertension on day 50, and another patient in the Thera-
curmin group had redness of the tongue on day 6. In addi-
tion, one patient in the placebo group felt unwell on day 7. 
The other three cases in the Theracurmin group dropped 
out because they underwent intra-articular injection of 
hyaluronic acid on weeks 2, 2 (different patient), and 3. 
There were two Kellgren–Lawrence grade II cases and 
one Kellgren–Lawrence grade III case. The initial VAS 
scores in these three cases were 1.0, 0.54, and 0.45, and 
the improved VAS scores before intra-articular injection 
of hyaluronic acid were 0, 0.10, and 0.29, respectively. 
Therefore, we included 41 patients (18 and 23 patients in 
the Theracurmin and placebo groups, respectively) for fur-
ther analysis.
The baseline characteristics of the study subjects in the 
two groups are shown in Table 1. Reflecting the general 
demographic profile of knee osteoarthritis, the majority of 
the subjects were female, with 77.8 % in the Theracurmin 
group and 78.3 % in the placebo group. The patient ages 
were also comparable between the two groups. The Kell-
gren–Lawrence criteria grade was used to quantify disease 
severity in order to effectively randomize disease status 
upon study entry between the groups. The majority of the 
subjects had grade II disease, with similar frequencies seen 
in the two groups. No statistical differences in the baseline 
characteristics were evident. Compliance was similar in the 
Theracurmin and placebo groups.
Although the improved VAS scores were not signifi-
cantly different between the two groups (P = 0.10) except 
Fig. 1  Study profile, including enrollments and dropouts. Seven 
patients in the Theracurmin group and two patients in the placebo 
group dropped out. Therefore, we analyzed 41 patients (18 patients in 
the Theracurmin group and 23 patients in the placebo group)
Table 1  Baseline 
characteristics of the study 
subjects in the two groups
No statistical differences in the 
baseline characteristics between 
the groups were evident
Theracurmin Placebo Total
Number of participants 18 23 41
 Male (%) 22.2 (4/18) 21.7 (5/23) 22.0 (9/41)
 Female (%) 77.8 (14/18) 78.3 (18/23) 78.9 (32/41)
Mean (SD) age (years) 71.9 (5.3) 66.1 (7.2) 68.7 (7.0)
Mean (SD) height (cm) 156.4 (7.0) 158.1 (7.6) 157.4 (7.3)
Mean (SD) body weight (kg) 61.5 (8.6) 62.1 (8.0) 61.8 (8.2)
Mean (SD) body mass index (kg/m2) 25.1 (2.7) 24.8 (2.3) 24.9 (2.4)
Osteoarthritis lesions
 Either left or right only (%) 72.2 (13/18) 56.5 (13/23) 63.4 (26/41)
 Both left and right (%) 27.8 (5/18) 43.5 (10/23) 36.6 (15/41)
Kellgren–Lawrence classification for knee osteoarthritis
 II (%) 72.2 (13/18) 87.0 (20/23) 80.5 (33/41)
 III (%) 27.8 (5/18) 13.0 (3/23) 19.5 (8/41)
Mean VAS score (SD) 0.52 (0.24) 0.42 (0.25) 0.47 (0.25)
Mean JOA score of each knee (SD) 82.5 (14.3) 84.8 (10.5) 83.8 (12.3)
Mean JKOM total score (SD) 35.5 (22.5) 27.0 (11.7) 307 (17.6)
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in the patients with initial VAS scores of 0.15 or less, the 
improved VAS scores were significantly higher in the 
Theracurmin group than in the placebo group at 8 weeks 
(Fig. 2). The mean VAS scores at 0 and 8 weeks in all 41 
cases were 0.52 and 0.20, respectively, in the Theracur-
min group, and 0.42 and 0.21, respectively, in the placebo 
group. Except the patients with initial VAS scores of 0.15 
or less, the mean VAS scores at 0 and 8 weeks were 0.60 
and 0.20, respectively, in the Theracurmin group, and 0.47 
and 0.23, respectively, in the placebo group. In each of 
the two groups there were three patients with initial VAS 
scores of 0.15 or less.
There were no statistically significant differences in 
the JKOM scores between the two groups. However, the 
improved scores in the JKOM total score (Fig. 3) and in 
each JKOM subcategory tended to be higher in the Thera-
curmin group than in the placebo group, especially from 
6 to 8 weeks in all 41 cases and 35 cases, except in the 
patients with initial VAS scores of 0.15 or less. There were 
no statistically significant differences in JOA total and sub-
category scores (data not shown) between the two groups.
At 8 weeks only, NSAIDs were needed significantly 
less in the Theracurmin group than in the placebo group 
(Fig. 4).
At 8 weeks, all laboratory test results were similar to the 
baseline scores in both groups with the following excep-
tions: there were slight increases in triglyceride levels in 
some patients at week 8 in both groups (two patients in the 
Theracurmin group and four patients in the placebo group), 
slight increases in the level of creatinine (one case in the 
Theracurmin group), uric acid (one case in the placebo 
group), and amylase (one case in the placebo group) as 
well slight decreases in red blood cells (two cases in the 
Theracurmin group) and cholinesterase levels (one case in 
the Theracurmin group). These were all minor changes, and 
no serious adverse events were observed in either group 
during this study.
Discussion
In this study, the knee pain VAS scores were significantly 
lower in the patients treated with Theracurmin than in those 
treated with placebo at 8 weeks among those who had ini-
tial VAS scores of >0.15. The same tendency was seen in 
Fig. 2  The improved VAS scores in the two groups are presented 
as means ± SDs. Except for the patients with initial VAS scores of 
0.15 or less, the improved VAS scores were significantly larger in the 
Theracurmin group than in the placebo group at 8 weeks (P = 0.023)
Fig. 3  The improved JKOM total scores for the two groups are 
shown as the means ± SDs
Fig. 4  NSAID necessity in the two groups. At 8 weeks only, the ratio 
of patients who needed celecoxib was significantly smaller in the 
Theracurmin group than in the placebo group (P = 0.0252)
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the total JKOM scores and its subcategorical scores, includ-
ing pain and stiffness in the knees, condition in daily life, 
general activities, and health conditions. Moreover, Thera-
curmin significantly lowered celecoxib dependence com-
pared with placebo. These results suggest that Theracurmin 
may decrease the pain and discomfort of knee osteoarthritis 
and improve the patient’s general condition and quality of 
daily life. Because osteoarthritis is a slowly progressive and 
chronic condition that decreases quality of life, agents like 
Theracurmin, which is also a common food ingredient that 
is mildly effective with no major side effects, has modest 
potential for the treatment of human knee osteoarthritis.
The patients in the Theracurmin group took six capsules 
of Theracurmin per day, and each capsule contained 30 mg 
curcumin. We confirmed the safety of a Theracurmin dose 
of 150–210 mg that healthy humans could take in the phase 
1 study. Therefore, six 30-mg capsules of Theracurmin per 
day were used in various clinical studies in our group, and 
no major side effects were observed.
In this study, the improved VAS scores between both 
groups were not significantly different, except in the patients 
with initial VAS scores of 0.15 or less. In each group, there 
were three patients with initial VAS scores of 0.15 or less. 
If the initial VAS score was small, the improved VAS score 
did not increase. This was because, when all 41 cases were 
considered, the improved VAS scores did not differ signifi-
cantly between both groups. Three cases in the Theracurmin 
group dropped out because they underwent intra-articular 
injection of hyaluronic acid. The initial VAS scores in these 
three cases were 1.0, 0.54, and 0.45, and the improved VAS 
scores before intra-articular injection of hyaluronic acid 
were 0, 0.10, and 0.29. Our results indicate that Theracur-
min was ineffective in some cases.
Some studies have suggested that curcumin has an effect 
on arthritis. Huang et al. [15] showed that curcumin dra-
matically attenuates the progression and severity of colla-
gen-induced arthritis in mice and suppresses the produc-
tion of the B-cell-activating factor belonging to the tumor 
necrosis factor family (a mechanism involved in rheuma-
toid arthritis). Banji D et al. [16] stated that combination 
treatment with methotrexate and curcumin had a significant 
anti-arthritic effect and protected against hematologic tox-
icity in rats. In addition to these anti-inflammatory effects, 
there curcumin seems to exert a chondroprotective action. 
For instance, Yang et al. [17] described novel pharmaco-
logical actions of curcumin on chondrocytes stimulated 
by advanced glycation end products. Kumar D et al. [18] 
also demonstrated that curcumin regulates the expression 
and secretion of various matrix metalloproteinases. Both 
the anti-inflammatory and chondroprotective effects of cur-
cumin provide strong support for the potential effectiveness 
of curcumin treatment for osteoarthritis, and may explain 
the results of our present study. Further studies may be 
needed to show the chondroprotective effect of Theracur-
min in knee osteoarthritis.
COX-2 inhibitors have been used as efficient anti-
inflammatory agents or for osteoarthritis, although their 
cardiovascular toxicity can be problematic during long-
time use. Lev-Ari et al. [19] reported a synergistic effect 
of celecoxib and curcumin that resulted in inhibition of 
the growth of osteoarthritic synovial adherent cells, which 
may be associated with increased induction of apoptosis, 
and stated that the synergistic effect was mediated by a 
mechanism that involved inhibition of COX-2 activity. In 
our study, Theracurmin decreased the need for the COX-2 
inhibitor celecoxib. However, before they discontinued 
celecoxib, the subjects took both celecoxib and Theracur-
min, so it is possible that there was a synergistic effect. 
Further study would be needed to clarify the best option 
among celecoxib alone, curcumin alone, and combined 
celecoxib and curcumin.
There have been three clinical reports that have exam-
ined the effects of curcumin in human osteoarthritic or 
rheumatic diseases. One pilot clinical study evaluated the 
safety and effectiveness of curcumin alone, diclofenac 
sodium alone, and their combination in patients with 
active rheumatoid arthritis [20]. Significantly greater 
improvement was shown by the curcumin group than by 
the diclofenac sodium group. More importantly, curcumin 
treatment was found to be safe and was not associated with 
adverse events. These results provided the first evidence for 
the safety and superiority of curcumin treatment in patients 
with active rheumatoid arthritis. With regard to curcumin’s 
effect on osteoarthritis, there have been two reported stud-
ies on the use of Meriva [21, 22], a complex of curcumin 
with soy phosphatidylcholine phytosomes, which have 
suggested that curcumin is efficacious for treating knee 
osteoarthritis. However, although these two studies were 
promising, both were open-label trials, not double-blind 
studies or randomized controlled trials with no restric-
tion on NSAIDs, other painkillers, and other treatments 
prescribed by the general practitioners. The present study, 
which was a double-blind placebo-controlled trial, showed 
that even the placebo group showed statistically significant 
effects on all criteria, including those of the JOA scale, 
VAS, and JKOM (including all four JKOM subcategories), 
even though we only allowed celecoxib as a concomitant 
drug. Therefore, to evaluate the effects of specific com-
pounds on knee osteoarthritis, we strongly believe that dou-
ble-blind placebo-controlled studies should be conducted, 
which means that the effect seen in the Meriva studies may 
not be certain. In contrast, our study clearly showed Thera-
curmin’s effectiveness for treating knee osteoarthritis in a 
double-blind placebo-controlled study.
Several studies of Theracurmin have been conducted 
in animals and humans, and it has been suggested to be 
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effective for treating cancer and cardiovascular conditions. 
For instance, two papers showing the clinical effective-
ness of Theracurmin have been published. One paper sug-
gested that regular endurance exercise combined with daily 
curcumin ingestion may decrease left ventricular afterload 
to a greater extent than monotherapy with either interven-
tion alone in postmenopausal women [23]. The other paper 
showed that curcumin ingestion and aerobic exercise train-
ing increased flow-mediated dilation in postmenopausal 
women, which suggested that both can potentially improve 
age-related decline in endothelial function [24]. Similar to 
the present study, there were no major adverse effects of 
Theracurmin in the two previous studies, in spite of Thera-
curmin’s much higher bioavailability.
Patients with rheumatoid arthritis or osteoarthritis need 
novel anti-arthritic therapies because of possible gastroin-
testinal and cardiovascular adverse events caused by current 
therapies using NSAIDs and COX-2 inhibitors. There have 
been some in vitro and in vivo studies of arthritis treatment 
using natural health products or functional food materials. 
Ahmed et al. [25] suggested that epigallocatechin-3-gallate 
could decrease synovial hyperplasia, cartilage degrada-
tion, and bone resorption by modulating multiple targets 
in joints. Resveratrol may also prevent intervertebral disc 
degeneration, osteoarthritis-associated inflammation, chon-
drocyte apoptosis, and rheumatoid arthritis-related pannus 
formation, which are desirable goals in the treatment of 
osteoarthritis and rheumatoid arthritis [26]. In contrast to 
NSAIDs, curcumin has no gastrointestinal side effects and 
can even protect the gastric mucosa. Therefore, curcumin 
is thought to be beneficial in the management of chronic 
inflammation-related joint disease, including osteoarthri-
tis [27]. However, because assessments of the outcomes of 
arthritis treatments are usually subjective, it is critical to 
confirm the effect of a test agent in double-blind placebo-
controlled studies. For instance, glucosamine and chon-
droitin, which have often been used by arthritis patients, 
were found to be no more effective than placebo, and using 
then in combination did not decrease joint pain or have an 
impact on joint space narrowing [28]. In the present dou-
ble-blind placebo-controlled study, we were able to provide 
the first evidence of the safety and superiority of curcumin 
treatment in patients with knee osteoarthritis. We also 
believe that we were able to obtain these results because 
of the high bioavailability of Theracurmin, which enhanced 
the health benefit of curcumin.
The limitations of our study were the small number of 
patients (n = 50) and short duration (8 weeks) of the treat-
ment of knee osteoarthritis. This was a pilot study to deter-
mine the effect of Theracurmin on knee osteoarthritis, but 
we were fortunately able to observe significant outcomes 
with respect to improved VAS scores and decreased NSAID 
(celecoxib) necessity. Future studies may be needed to 
validate our findings in a large number of patients with 
knee osteoarthritis over a longer duration.
In our evaluations, we used JKOM, which was designed 
for Japanese patients with knee osteoarthritis, and did not 
use WOMAC, which is commonly used throughout the 
world; however, JKOM has been validated and is widely 
used in Japan.
In conclusion, we conducted a randomized, double-
blind, placebo-controlled, prospective clinical study of the 
efficacy of Theracurmin, which is a highly bioavailable 
form of curcumin, in patients with osteoarthritis. Thera-
curmin was significantly effective in deceasing pain and 
NSAID necessity with no major adverse events. Theracur-
min has modest potential for the treatment of human knee 
osteoarthritis in the future.
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